Cancer News and Research

Latest Cancer News and Research

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

Acute hepatocellular injury is a commonly encountered phenomenon in patients with cholelithiasis and concomitant common bile duct (CBD) stones. However, in clinical practice, it seemed to occur also in cholelithiasis patients without evidence of CBD stones. Its incidence and final outcome necessitated clarification.

26 Aug 2009

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

BioDelivery Sciences International, Inc. today announced the issuance of United States Patent 7,579,019, which will provide additional patent exclusivity for both ONSOLIS and BDSI’s BEMA drug delivery technology platform until at least 2019.

26 Aug 2009

MicroRNAs in saliva could aid in the detection of oral cancer

Researchers continue to add to the diagnostic alphabet of saliva by identifying the presence of at least 50 microRNAs that could aid in the detection of oral cancer, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

26 Aug 2009

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA.

25 Aug 2009

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

A new study published by researchers at the UCLA School of Dentistry substantiates the effectiveness of measuring the microRNAs present in saliva to detect oral squamous cell carcinoma. Like hall monitors in an elementary school, microRNAs are the molecules produced by cells that simultaneously asses the behavior of multiple genes and control their activity.

25 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

The Cancer Center picks ATCi's Simulsat broadcast system to extend its critical broadcast applications

Antenna Technology Communications Inc., a provider of satellite communications systems, today announced that one of the largest university-based cancer research centers has selected the ATCi Simulsat C/Ku Multibeam antenna solution and related satellite equipment to outfit its central headquarters.

25 Aug 2009

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate $5 million of gross proceeds through a private placement of units ("August 2009 Private Placement") and through the exercise of warrants (the "Warrant Exchange") originally issued in connection with its May/June 2008 private placement.

25 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business.

25 Aug 2009

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

University of Manchester researchers found that a special type of the chemicals known as 'kinase inhibitors' opened up communication channels on the surface of cells that enabled healthy cells to 'talk' to the cancer cells.

From The University of Manchester 25 Aug 2009

Cord Blood America announces retirement of $1.6 million in debt since July 2009

Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.

25 Aug 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

...

25 Aug 2009

NCI investigator’s endorsement of of inaccurate high-risk HPV test to refer women to cervical cancer tests is “unfortunate and inappropriate” says Sin Hang Lee

A National Cancer Institute (NCI) investigator’s endorsement of inaccurate high-risk HPV test to refer women to cervical cancer tests, despite the weak evidence of its value, is “unfortunate and inappropriate.”

25 Aug 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

The NanoBusiness Alliance, the world's leading nanotechnology trade association, today announced details of its expanded conference program for the 8th annual NanoBusiness 2009 conference and exhibition, which will held at McCormick Place in Chicago, IL, from September 8 – 10.

25 Aug 2009

Awareness campaign on sun protection by Portland dermatologists at the LPGA Safeway Classic

In a region known more for its rainfall than sunshine, a team of Portland dermatologists representing the Women's Dermatologic Society (WDS) will return for the third time in six years to the LPGA Safeway Classic to promote sun safety for all seasons and skin types. This picturesque yet often cloudy venue has proven to draw golf lovers who need greater awareness about skin protection, as shown by the previous screenings' 37% skin cancer discovery rate.

25 Aug 2009

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Cancer News and Research

Latest Cancer News and Research

Research indicates that acute hepatocellular injury in cholelithiasis and cholecystitis without choledocholithiasis is mild and transient

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

MicroRNAs in saliva could aid in the detection of oral cancer

University of Maryland researchers perform a genome-wide association study of ADP-stimulated platelet aggregation

MicroRNAs present in saliva could be used to detect oral squamous cell carcinoma

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

The Cancer Center picks ATCi's Simulsat broadcast system to extend its critical broadcast applications

Raptor Pharmaceuticals raises funds to execute its corporate strategy

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Shire collaborates with Santaris Pharma to develop Locked Nucleic Acid technology

University of Manchester researchers discover kinase inhibitors for treating early-stage cancers

Cord Blood America announces retirement of $1.6 million in debt since July 2009

MEDRAD and USF sign research agreement to study FDG administration effect on the workflow for PET imaging procedures

NCI investigator’s endorsement of of inaccurate high-risk HPV test to refer women to cervical cancer tests is “unfortunate and inappropriate” says Sin Hang Lee

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

NanoBusiness 2009 conference to address nanotechnology advancements in various markets

Awareness campaign on sun protection by Portland dermatologists at the LPGA Safeway Classic

Bavarian Nordic begins negotiations with U.S. to secure a contract to develop a freeze-dried version of smallpox vaccine

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in